United Immunity, Co., Ltd.

United Immunity, Co., Ltd. is at the forefront of biotechnology research, dedicated to delivering innovative clinical experiences for patients facing cancer and infectious diseases. By uniting the power of immunity and nanoparticle technology, United Immunity, Co., Ltd. is changing the future of patient care through proactive and selective targeting of myeloid cells.

United Immunity, Co., Ltd. is developing cutting-edge nanoparticle and lipid nanoparticle (LNP) technologies based on Cholesteryl Pullulan. These advanced technologies selectively deliver therapeutic agents to macrophages, dendritic cells, and other myeloid cells, including tumor-associated macrophages (TAM), Kupffer cells in the liver, adipose tissue macrophages, and microglia. Located at 1-12-3, Nihonbashi-Muromachi, Chuo-ku, Tokyo, 103-0022, JP, United Immunity, Co., Ltd. is strategically positioned to drive advancements in targeted therapies. An additional location at 6-3-7 Minatojima-Minamimachi, Chuo-ku, Kobe, 650-0047, JP, further supports their research and development efforts.

United Immunity's Pullulan nanoparticle (PNP) and Pullulan LNP (P-LNP) technologies are ideally suited for cancer and infectious disease vaccines, with potential applications in treating fibrosis, inflammation, autoimmune, and metabolic diseases. Their lead program, UI-102, leverages pullulan nanoparticles to precisely deliver a Toll-like receptor (TLR) agonist to M2-like tumor macrophages, modulating the tumor microenvironment from “cold (immune-suppressed)” to “hot (immune-activated).” United Immunity, Co., Ltd. aims to increase the efficacy of checkpoint inhibitors and other immunotherapy agents while significantly reducing safety risks associated with TLR agonism. The company is also using its technology to boost the effectiveness of T-cell therapies and generate in vivo CAR-macrophages. To the manager of United Immunity, Co., Ltd., we invite you to create a customized and exclusive company showcase and product listing on our platform.